Pharmacology

Action Mechanism of Action Reference
INHIBITOR Elongation factor 2 inhibitor PubMed FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lymphoma 3 D008223 ClinicalTrials
Lymphoma, T-Cell, Peripheral 3 D016411 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Leukemia, Myeloid, Acute 2 D015470 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Lymphoma, Non-Hodgkin 2 D008228 ClinicalTrials
Graft vs Host Disease 2 D006086 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Leukemia, Biphenotypic, Acute 2 D015456 ClinicalTrials
Fallopian Tube Neoplasms 2 D005185 ClinicalTrials
Peritoneal Neoplasms 2 D010534 ClinicalTrials
Fallopian Tube Neoplasms 2 D005185 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Breast Neoplasms, Male 1 D018567 ClinicalTrials
Carcinoma, Endometrioid 1 D018269 ClinicalTrials
Multiple Myeloma 1 D009101 ClinicalTrials
Cystadenoma, Serous 1 D018293 ClinicalTrials
Kidney Neoplasms 0 D007680 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Blood and lymphatic system disorders
15.38
General disorders and administration site conditions
12.09
Vascular disorders
10.99
Infections and infestations
9.89
Metabolism and nutrition disorders
7.69
Nervous system disorders
6.59
Respiratory, thoracic and mediastinal disorders
5.49
Eye disorders
4.4
Gastrointestinal disorders
3.3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.3
Skin and subcutaneous tissue disorders
3.3
Cardiac disorders
2.2
Endocrine disorders
2.2
Hepatobiliary disorders
2.2
Immune system disorders
2.2
Investigations
2.2
Musculoskeletal and connective tissue disorders
2.2
Psychiatric disorders
2.2

Cross References

Resources Reference
CAS NUMBER 173146-27-5
ChEMBL CHEMBL1201550
FDA SRS 25E79B5CTM
Guide to Pharmacology 7044